The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's Enhertu in combination with Roche ...
AstraZeneca, Eastman, Kraft Heinz, and P&G have been recognized for their outstanding contribution at the recent OMP ...
FDA approval moves trastuzumab deruxtecan in combination with pertuzumab into frontline treatment of unresectable or ...
Datopotamab Deruxtecan powder for concentrate for solution for infusion 100 mg (r-DNA origin) is indicated for the treatment ...
Policy swings have made it a slippery year for pharma ...
Israeli drug discovery and development company Compugen (Nasdaq: CGEN; TASE: CGEN) today announced changes in its ...
2d
AstraZeneca, Daiichi Sankyo's Enhertu Regimen Greenlit as First-line Breast Cancer Treatment in US
AstraZeneca (AZN.L, AZN.ST) on Monday said Enhertu plus pertuzumab won approval in the US as the first-line treatment of ...
U.S. President Donald Trump in July sent letters to 17 drugmakers urging them to slash prices. Pfizer and AstraZeneca first ...
Patients with eosinophilic granulomatosis with polyangiitis who received 2 years of treatment with the interleukin-5 ...
The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as ...
Rilvegostomig is a first-in-class dual-checkpoint bispecific therapy that delivers coordinated PD-1 and TIGIT blockade on the same immune effector cell. AstraZeneca is currently advancing the drug in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback